Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...919293949596979899100101...123124»
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  TACE Combined With Lenvatinib and Sintilimab for Advanced HCC (clinicaltrials.gov) -  Jan 6, 2021   
    P2,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, Checkpoint inhibition:  Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. (Pubmed Central) -  Jan 1, 2021   
    Since the introduction of sorafenib in 2007, many other systemic treatments have been investigated...It took more than ten years before lenvatinib could be added as alternative first-line treatment option...Several reviews reported on the latest phase 1/2 studies and discussed the higher response rates and better tolerability when compared to current standard of care therapies. This review will focus on elaborating the working mechanism of these checkpoint inhibitors, give an elaborate update of the therapeutic agents that are currently available or under research, and will give an overview of the latest trials, as well as ongoing and upcoming trials.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. (Pubmed Central) -  Dec 31, 2020   
    This review will focus on elaborating the working mechanism of these checkpoint inhibitors, give an elaborate update of the therapeutic agents that are currently available or under research, and will give an overview of the latest trials, as well as ongoing and upcoming trials. These data collectively provided evidence that FGFR1 overexpression could be a potential cause of lenvatinib resistance and Oxysophocarpine could be an ideal combined therapy with lenvatinib in HCC treatment.
  • ||||||||||  OvaSave (ovalbumin) / Sangamo Therapeutics
    Journal:  Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis. (Pubmed Central) -  Dec 30, 2020   
    Bioinformatic analysis and molecular biological characterization revealed that VEGF-C is negatively regulated by an orphan nuclear receptor, chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII)...Autotransplanted mouse model of endometriosis showed lenvatinib treatment abrogated the increased lymphatic vessels development in the endometriotic lesion, enlarged retroperitoneal lymph nodes, and immune cells infiltration, indicating that blocking VEGF-C signaling can reduce local chronic inflammation and concomitantly endometriosis development...Taken together, we identify the vicious cycle of inflammation, COUP-TFII, VEGF-C, and lymphangiogenesis in the endometriotic microenvironment, which opens up new horizons in understanding the pathophysiology of endometriosis. VEGF-C not only can serve as a diagnostic biomarker but also a molecular target for developing therapeutic regimens.
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Enrollment change, PD(L)-1 Biomarker:  TALENT: Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (clinicaltrials.gov) -  Dec 29, 2020   
    P2,  N=4, Recruiting, 
    VEGF-C not only can serve as a diagnostic biomarker but also a molecular target for developing therapeutic regimens. Not yet recruiting --> Recruiting | N=27 --> 4
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    New P3 trial, Metastases:  Sorafenib or Lenvatinib Plus HAIC of 130 mg/m (clinicaltrials.gov) -  Dec 28, 2020   
    P3,  N=400, Recruiting, 
  • ||||||||||  everolimus / Generic mfg., lenvatinib / Generic mfg.
    Clinical, Journal:  Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report. (Pubmed Central) -  Dec 23, 2020   
    To our knowledge, we describe for the first time a case of a patient with heavily pretreated metastatic pRCC who benefited from the combination of lenvatinib plus everolimus for more than 2 years. According to immunohistologic and biological findings in our patient both on primary tumor and liver metastasis, we hypothesize that selected patients with metastatic pRCC, progressed to standard/available treatments (including angiogenic drugs, mTOR inhibitors, and immunotherapy) and dissociated response to everolimus, could benefit from adding lenvatinib to everolimus.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT (clinicaltrials.gov) -  Dec 20, 2020   
    P=N/A,  N=30, Recruiting, 
    Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Dec 2022 --> Oct 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Review, Journal:  Therapy in Advanced Hepatocellular Carcinoma. (Pubmed Central) -  Dec 19, 2020   
    Second-line agents include cabozantinib, regorafenib, ramucirumab, and nivolumab...Locoregional therapies such as transarterial chemoembolization and radioembolization have shown a potential benefit in selected patients with advanced HCC. In this review, we aim to summarize the treatment options available for advanced HCC.
  • ||||||||||  lenvatinib / Generic mfg.
    [VIRTUAL] An Optimized Neoantigen Load Model Based on Immune Editing to Predict Response and Prognosis of Immune Checkpoint Therapy (ePoster Hall) -  Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_304;    
    Results We applied oTNL to three tumor immunotherapy cohorts, including 65 cases of NSCLC treated with anti-PD-1/PD-L1, 30 cases of melanoma treated with anti-PD-1 and 15 cases of ICC treated with anti-PD-1 plus lenvatinib...Identifying neoantigen clones with the ability of inducing immune elimination would help to better predict the efficacy of immunotherapy. Our new optimized mathematical model could predict the response and prognosis of patients with lung cancer, melanoma and intrahepatic cholangiocarcinoma, and have better predicting value than prior's genetic method.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. (Pubmed Central) -  Dec 16, 2020   
    The treating physician should choose an appropriate treatment according to the patient's age, comorbidities, and tolerability of previous checkpoint inhibitors, among other considerations. Cases of patients with renal cell carcinoma refractory to checkpoint inhibitor treatment are growing, warranting a review of the activity and safety of target therapies after immunotherapy.
  • ||||||||||  volrustomig (MEDI5752) / AstraZeneca
    Enrollment change, Trial completion date, Trial primary completion date:  A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Dec 16, 2020   
    P1b,  N=77, Recruiting, 
    Cases of patients with renal cell carcinoma refractory to checkpoint inhibitor treatment are growing, warranting a review of the activity and safety of target therapies after immunotherapy. N=52 --> 77 | Trial completion date: Mar 2022 --> Jun 2023 | Trial primary completion date: Mar 2022 --> Jun 2023
  • ||||||||||  everolimus / Generic mfg., paclitaxel / Generic mfg.
    Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  Recent advances in the management of anaplastic thyroid cancer. (Pubmed Central) -  Dec 10, 2020   
    Surgery should be as complete as possible, securing the airway and ensuring access for nutritional support; the current standard of care of radiotherapy is the intensity-modulated radiation therapy; chemotherapy includes the use of doxorubicin or taxanes (paclitaxel or docetaxel) generally with platin (cisplatin or carboplatin)...These include multitarget tyrosine kinase inhibitors (Lenvatinib, Sorafenib, Sunitinib, Vandetanib, Axitinib, Pazopanib, Pyrazolo-pyrimidine compounds), single target tyrosine kinase inhibitors (Dabrafenib plus Trametinib and Vemurafenib against BRAF, Gefitinib against EGFR, PPARγ ligands (e.g. Efatutazone), Everolimus against mTOR, vascular disruptors (e.g. Fosbretabulin), and immunotherapy (e.g. Spartalizumab and Pembrolizumab, which are anti PD-1/PD-L1 molecules)...Other single target mutation agents with fair results are Everolimus when a mutation involving the PI3K/mTOR pathway is detected, Imatinib in case of PDGF-receptors overexpression, and Spartalizumab in case of PD-L1 positive tumors...Since in this tumor several genetic alterations are usually found, the aim is to inhibit or disrupt several pathways: these combination strategies use therapy targeting angiogenesis, survival, proliferation, and may act against both MAPK and PI3K pathways. Investigating new treatment options is eagerly awaited since, to date, even the molecules with the best radiological results have not been able to provide a durable disease control.